B+
Bull case
25%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
MDCX
MedicusCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Multiple clinical programs, regulatory authorizations and Pfizer's expected continued involvement in CD228V provide several potential validation paths. Successful trial execution or clearer partner-funded development could be material relative to MDCX's approximately $16.4 million market capitalization.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Equity, ATM or debt financing could dilute shareholders or add restrictive financing costs.
Momentum
11
Value
41
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.17 · Bull $0.32 · Bear $0.07Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $4.48
Why
Momentum11 · Δ7d -
Value41 · Δ7d -0.0
Sentiment75 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Equity, ATM or debt financing could dilute shareholders or add restrictive financing costs.
- • Micro-cap liquidity and event-driven volatility can produce price moves disconnected from fundamental value.
- • MDCX remains a loss-making micro-cap biotechnology issuer with substantial clinical uncertainty.
Catalyst clock
2026-11-15
Cash runway and dilution checkpoint
Lead driver: Sentiment · See AI snapshot
Momentum
11
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-5.2
Sentiment
75
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 10.9 / Value 41.2 / Sentiment 74.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.17
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.07
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$16.43M
Beta
-
Shares Out
22.03M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.98
Rev YoY
-
EPS YoY
-51.2%
Gross Margin
-
Op Margin
-
Net Debt
-$2.36M
Current Ratio
1.57
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data